Acknowledgement

This activity is provided by Talem Health and ACCESS Oncology.


This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
• Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for oncologists and other health professionals practicing in community settings, including those who serve geographically diverse populations.

Program Overview

While gastric and gastroesophageal junction (GEJ) cancers are relatively uncommon in the United States, the disease is not typically diagnosed until later states, and 5-year relative survival remains low. Fortunately, recent progress in the identification of molecular subtypes of gastric/GEJ cancers and novel targeted therapies, including immunotherapies, have led to biomarker-guided treatment selection and improved outcomes for patients. In this on-demand CME/CE activity, expert faculty will review strategies for effective treatment and collaborative management of gastric and GEJ cancers in the community oncology setting. The program will highlight the role of biomarker testing in clinical practice and review current and emerging systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers. Participants from a recent Gastric Cancer Project ECHO^® initiative will also share their unique insights on challenges and lessons learned while caring for individuals with gastric and GEJ cancers in community-based settings. 

The content for this enduring activity was recorded on June 29, 2026.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Apply biomarker testing of gastric/GEJ tumors to improve understanding of patient prognosis and guide treatment decisions
• Describe the mechanism of action of novel systemic therapies for unresectable locally advanced or metastatic gastric/GEJ cancers
• Evaluate clinical evidence on the safety and efficacy of current and emerging systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers
• Implement team-based strategies for monitoring and managing adverse events associated with systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers

Faculty

Matthew R. Strickland, MD 
Instructor in Medicine
Harvard Medical School
Medical Oncologist
Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital Cancer Center
Boston, MA

Ilyas Sahin, MD
Medical Oncologist
Massachusetts General Hospital Cancer Center
Boston, MA

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-26-009-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty

Matthew R. Strickland, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Astellas, Inc., AstraZeneca Pharmaceuticals, Bayer, Bristol Myers Squibb, Encapsulate, and SOPHIE. 

Ilyas Sahin, MD, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer 

None of the Talem Health staff (planners, managers, or reviewer) for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements 

Supported Browsers: 
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets: 
All devices

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

©ACCESS Oncology, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited. 

Media 

Internet activity 

Fee Information 

There is no fee for this educational activity. 

Contact Information 

For questions about this activity, please contact ACCESS Oncology (a division of Talem Health) at 800-913-9370 or cme@accessoncologyce.com.